01.06.14
New Haven, Conn.-based Soft Tissue Regeneration Inc. (STR), maker of regenerative orthopedic devices for tendon and ligament repair, has completed a round of financing and has added of three new members to its board of directors. The $5 million financing commitment will permit STR to complete its 15-patient European Phase I clinical study which enrolled its first patient June of last year; and continue the U.S. Food and Drug Administration (FDA) regulatory process for the its L-C Ligament, a bioresorbable, implantable scaffold for the repair and regeneration of an injured or torn anterior cruciate ligament (ACL). In conjunction with this financing, Dane Miller, Ph.D., Charles Hart, Ph.D., and Richard Emmitt are joining the STR board of directors.
“STR has quickly progressed from a concept to a real product that is already demonstrating clinically its potential to provide surgeons and their ACL patients with an alternative to the inherent morbidity and risks of autograft or allograft tendon,” said Joseph Reilly, president, CEO, and co-founder of STR. “The new members of the board of directors offer years of experience and the guidance and insight that will allow us to continue making clinical and regulatory advances.”
The new members to the STR board of directors include:
Dane Miller, Ph.D. – Miller is the founder, current member of the board of directors, and former president and CEO of Biomet, a pioneer and leading company in the orthopedic industry. Miller offers insights and knowledge from his more than 40 years of experience and is considered one of the most distinguished entrepreneurs and executives in the medical device industry.
Charles Hart, Ph.D. – Hart is the former chief scientific officer and vice president of two of the pioneers in the field of regenerative medical technology, Advanced BioHealing and BioMimetics. He has more than 30 years of experience in commercializing advances in biomaterials and biotechnology.
Richard Emmitt – Emmitt is a general partner with The Vertical Group, a leading venture capital firm focused on the medical device industry. During his 40-year career, he has invested in and served as a member of the board of directors at several of the most successful medical device companies.
“STR has quickly progressed from a concept to a real product that is already demonstrating clinically its potential to provide surgeons and their ACL patients with an alternative to the inherent morbidity and risks of autograft or allograft tendon,” said Joseph Reilly, president, CEO, and co-founder of STR. “The new members of the board of directors offer years of experience and the guidance and insight that will allow us to continue making clinical and regulatory advances.”
The new members to the STR board of directors include:
Dane Miller, Ph.D. – Miller is the founder, current member of the board of directors, and former president and CEO of Biomet, a pioneer and leading company in the orthopedic industry. Miller offers insights and knowledge from his more than 40 years of experience and is considered one of the most distinguished entrepreneurs and executives in the medical device industry.
Charles Hart, Ph.D. – Hart is the former chief scientific officer and vice president of two of the pioneers in the field of regenerative medical technology, Advanced BioHealing and BioMimetics. He has more than 30 years of experience in commercializing advances in biomaterials and biotechnology.
Richard Emmitt – Emmitt is a general partner with The Vertical Group, a leading venture capital firm focused on the medical device industry. During his 40-year career, he has invested in and served as a member of the board of directors at several of the most successful medical device companies.